OMO-1 reduces progression and enhances cisplatin efficacy in a 4T1-based non-c-MET addicted intraductal mouse model for triple-negative breast cancer

por Jonas Steenbrugge, Niels Vander Elst, Kristel Demeyere, Olivier De Wever, Niek N. Sanders, Wim Van Den Broeck, Eric Ciamporcero, Timothy Perera, Evelyne Meyer
Publicado 2021